NCT00800462CompletedPhase 4
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
Toronto Rehabilitation Institute2 sites in 1 country23 target enrollmentStarted: March 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 23
- Locations
- 2
- Primary Endpoint
- Frequency of Incontinence Episodes
Study Overview
Brief Summary
This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female patients, between 18 and 75 years of age. Female patients of childbearing potential* must have a negative urine pregnancy test result on the day of Screening Visit and practice a reliable method of contraception**
- •*A female is considered of childbearing potential unless she is:
- •Postmenopausal for at least 12 months prior to study drug administration;
- •Without a uterus and/or both ovaries; or
- •Has been surgically sterilized for at least 6 months prior to study drug administration.
- •**Reliable methods of contraception include:
- •Hormonal methods or intrauterine device in use at least 30 days prior to study drug administration;
- •Barrier methods plus spermicidal in use at least 14 days prior to study drug administration; or
- •Sexual abstinence as a lifestyle.
- •Patients with a neurogenic bladder and detrusor overactivity secondary to a spinal cord injury.
- •Patients with urinary incontinence (minimum of one occurrence per day) despite current treatment. [NOTE: Bladder emptying may be accomplished with straining, intermittent catheterization (IC), spontaneous micturition or leakage episodes.]
- •Patients with serum creatinine within normal limits and normal renal function
- •Patients on a stable dose (minimum one month) of concomitant medication for Neurogenic detrusor overactivity
- •Patients must have adequate cognitive function to understand the requirements of the study, including completing questionnaires and signing a written Informed Consent.
Exclusion Criteria
- •Female patients who are pregnant (positive urine pregnancy test), planning to become pregnant during the study period, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
- •Patients with a history of transurethral sphincterotomy, bladder neck or prostatic resection, previous bladder surgery including myomectomy or augmentation cystoplasty.
- •Patients with chronic indwelling catheters.
- •Patients with, in the opinion of the Investigator, unstable or stable multiple sclerosis.
- •Patients with known, uncontrolled systemic disease.
- •Patients with evidence of recent alcohol/drug abuse.
- •Patients with urinary retention, gastrointestinal obstructive disorders or uncontrolled narrow-angle glaucoma.
- •Patients with contraindications to Trosec™, Enablex™ and Uromax®.
- •Patients who, in the opinion of the Investigator, have a significant condition or situation that may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
- •Patients with a history of poor cooperation, non-compliance, or unreliability.
- •Patients currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Screening Visit.
- •Patients administered anticholinergics and/or antispasmodic drugs during the course of the study.
- •Patient with hepatic insufficiency.
- •Patient has been administered intravesical botulinum toxin within 6 months prior to the Screening Visit and/or is expected to receive intravesical botulinum toxin during the course of the study.
- •Patient has any medical condition that would interfere with the interpretation of the study results or the conduct of the study.
Arms & Interventions
Oxybutynin Cl
Active Comparator
Intervention: Oxybutynin Cl (Drug)
Trospium Cl
Active Comparator
Intervention: Trospium Cl (Drug)
Darifenacin Hydrogren Bromide (HBr)
Active Comparator
Intervention: Darifenacin Hydrogen Bromide (HBr) (Drug)
Outcomes
Primary Outcomes
Frequency of Incontinence Episodes
Time Frame: 3 days
Adverse Event Reporting
Time Frame: Each Study Visit and Follow-up Phone Call
Secondary Outcomes
- Questionnaires(Monthly)
- Urodynamic Study(Baseline and 3 months)
Investigators
Magdy Hassouna
MD PhD FRCSC FACS
Toronto Rehabilitation Institute
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 4
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With MonotherapyHypertensionNCT02433119Dong-A ST Co., Ltd.238
Completed
Phase 1
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.Diabetes Mellitus Type 2NCT00517465Hoffmann-La Roche41
Completed
Phase 4
A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease PatientsRespiratory DiseaseNCT03334916Yuhan Corporation223
Completed
Phase 4
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency VirusHepatitis C, ChronicNCT02761629Hoffmann-La Roche180
Not yet recruiting
Phase 1
Mesenchymal Stem Cell Therapy for Knee OsteoarthritisOsteoarthritis, KneeNCT05288725Next Generation Regenerative Medicine LLC120